CD5-targeted CAR-NK therapy for T-cell cancers

Clinical Study of CD5 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/Refractory T-Cell Hematologic Malignancies

This study is testing a new type of treatment using special immune cells to see if it can help people with tough-to-treat T-cell cancers feel better when other treatments haven't worked.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Chongqing Precision Biotech Co., Ltd (Industry-sponsored)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Wuhan, Hubei)
• Trial ID: NCT06909474 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the safety and efficacy of anti-CD5 CAR-NK cell therapy in patients with relapsed or refractory T-cell hematologic malignancies. It is a single-arm, open-label trial that includes three dose groups to determine the optimal dose of CAR-NK cells. Patients will receive an initial infusion of CAR-NK cells, and if their response is suboptimal, they may receive a second infusion based on their condition. The study aims to provide a new treatment option for patients who have not responded to standard therapies.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-75 with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma.

Not a fit: Patients with non-T-cell hematologic malignancies or those who do not meet the specific eligibility criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this therapy could offer a new treatment option for patients with difficult-to-treat T-cell malignancies.

How similar studies have performed: While CAR-NK therapies are a novel approach, similar studies targeting other malignancies have shown promising results.

Eligibility criteria

Inclusion Criteria:

\-

1.Gender and Age: No gender restriction; age 18-75 years (inclusive). 2.Diagnosis: Confirmed diagnosis of T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoma, including:

1. T-ALL Patients: Bone marrow morphology during screening shows ≥5% blasts/immature lymphocytes and/or flow cytometry confirms minimal residual disease (MRD)+, and meets any of the following:

   1. Refractory to ≥2 cycles of standard induction chemotherapy (failure to achieve CR).
   2. Relapsed within 12 months after achieving CR with first-line induction therapy.
   3. Failure to achieve CR or relapse after ≥2 lines of chemotherapy.
   4. Relapse after hematopoietic stem cell transplantation (HSCT).
2. T-cell Lymphoma Patients: Confirmed diagnosis of T-lymphoblastic lymphoma (T-LBL) or T-cell non-Hodgkin lymphoma (including but not limited to: peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), extranodal NK/T-cell lymphoma (ENKL), T-cell prolymphocytic leukemia (T-PLL), adult T-cell leukemia/lymphoma (ATLL), mycosis fungoides/Sézary syndrome (MF/SS) stage IIB or higher), and meets both:

   1. At least one bidimensionally measurable lesion per Lugano 2014 criteria: nodal lesions \>1.5 cm in long axis; extranodal lesions \>1.0 cm in long axis.
   2. Refractory to ≥2 lines of chemotherapy, primary resistance, or relapse post-HSCT.

      3.CD5 Positivity: Confirmed by flow cytometry (≥80% tumor cells express CD5 with mean fluorescence intensity \[MFI\] equivalent to normal T cells; Dim defined as MFI ≥1 log lower than normal T cells; partial positivity defined as 20-80% tumor cells expressing CD5) or immunohistochemistry (\>30% tumor cells express CD5).

      4.ECOG Performance Status: 0-2 . 5.Life Expectancy: ≥12 weeks. 6.Organ Function:

   <!-- -->

   1. Cardiac: Left ventricular ejection fraction (LVEF) ≥50% by echocardiography; no significant ECG abnormalities.
   2. Renal: Serum creatinine ≤2.0×ULN.
   3. Hepatic: ALT/AST ≤3.0×ULN (≤5.0×ULN if liver involvement); total bilirubin ≤2.0×ULN.
   4. Pulmonary: Oxygen saturation ≥92% (room air). 7.No Contraindications: To leukapheresis, venipuncture, or cell collection. 8.No Severe Psychiatric Disorders. 9.Contraception: Agreement to use effective contraception from informed consent until 1 year post-CAR-NK infusion (for patients of childbearing potential).

      10.Informed Consent: Signed by the patient or legal guardian, confirming understanding of the trial's purpose and procedures.

Exclusion Criteria:

1. Prior CAR-NK therapy or genetically modified cell therapy.
2. Active CNS involvement at screening (prior CNS involvement with resolved status post-treatment is allowed).
3. Recent Anticancer Therapy:

   1. Chemotherapy, targeted therapy, or investigational drugs within 2 weeks or 5 half-lives prior to screening.
   2. Radiotherapy within 2 weeks prior to screening.
4. Active/Uncontrolled Infection: Within 1 week prior to screening.
5. Cerebrovascular Event or Seizure: Within 6 months prior to screening.
6. Viral Infections:

   1. HBV DNA \> ULN (if HBsAg+ or HBcAb+).
   2. HCV RNA \> ULN (if HCV Ab+).
   3. HIV+, syphilis+, or active tuberculosis.
7. Cardiac Disease:

   1. NYHA Class III/IV congestive heart failure.
   2. Myocardial infarction or CABG ≤6 months prior.
   3. Clinically significant ventricular arrhythmia or unexplained syncope (excluding vasovagal/dehydration-related).
   4. Severe cardiomyopathy.
8. Active/Uncontrolled Autoimmune Disease.
9. Prior Malignancy: Within 5 years, except for cured cervical carcinoma in situ, basal/squamous skin cancer, localized prostate cancer, or ductal carcinoma in situ.
10. Live Vaccination: Within 4 weeks prior to screening.
11. Pregnancy/Lactation: Pregnant, breastfeeding, or planning pregnancy within 1 year post-CAR-NK infusion.
12. Other: Investigator-determined ineligibility.

Where this trial is running

Wuhan, Hubei

• Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology — Wuhan, Hubei, China (Recruiting)

Study contacts

• Study coordinator: Jia Wei, MD

Conditions T-ALL/Lymphoma; T-ALL; T-LBL; PTCL-NOS; AITL; ALCL; ENKL; T-PLL